Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAT Study of cabozantinib in relapsing IDH-wildtype, MET-amplified glioblastoma
2022-000391-19Phase 2Terminated
- Sponsor
- Azienda Ospedaliera Santa Maria di Terni
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in glioblastoma (GBM), sponsored by Azienda Ospedaliera Santa Maria di Terni. Primary endpoint: 6-month progression-free survival rate. Started Feb 2022; status: terminated.
02
Drugs
cabozantinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2022-000391-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000391-19.